Health Care [ 8/12 ] | Biotechnology [ 34/74 ]
NASDAQ | Common Stock
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.
The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.
It has a collaboration agreement with Northway Biotechpharma and BiBo Biopharma Engineering Co., Ltd. for the supply of pegozafermin. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 26, 25 | -1.02 Decreased by -104.00% | -0.76 Decreased by -34.32% |
| Nov 6, 24 | -1.39 Decreased by -208.89% | -0.64 Decreased by -117.19% |
| Aug 5, 24 | -0.48 Increased by +7.69% | -0.57 Increased by +15.79% |
| May 9, 24 | -0.54 Increased by 0.00% | -0.46 Decreased by -17.39% |
| Feb 29, 24 | -0.50 Decreased by -4.17% | -0.49 Decreased by -2.04% |
| Nov 8, 23 | -0.45 Increased by +21.05% | -0.53 Increased by +15.09% |
| Aug 9, 23 | -0.52 Increased by +57.72% | -0.41 Decreased by -26.83% |
| May 4, 23 | -0.54 Increased by +57.14% | -0.52 Decreased by -3.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by -100.00% | -118.35 M Decreased by -194.16% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -149.07 M Decreased by -329.30% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -47.97 M Decreased by -24.95% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -51.68 M Increased by +38.56% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 234.00 K Increased by +N/A% | -40.23 M Decreased by -63.54% | Decreased by -17.19 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -34.73 M Decreased by -29.55% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -38.39 M Decreased by -51.33% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -84.12 M Decreased by -229.05% | Decreased by N/A% Decreased by N/A% |